Literature DB >> 6407189

The pathogenesis of trypanosomiasis of the CNS. Studies on parasitological and neurohistological findings in trypanosoma rhodesiense infected vervet monkeys.

H Schmidt.   

Abstract

Parasitological examinations of the cerebrospinal fluid of 20 vervet monkeys (Cercopithecus aethiops), that had been infected with Trypanosoma rhodesiense, revealed that the CSF was regularly infested with trypanosomes in the early phase of the disease, at the earliest on the 13th day, in most of the animals in the 3rd or 4th week, after infection. Follow-up examinations of the CSF during the further course of the disease also regularly proved positive for trypanosomes. Histological studies in the animals that died at a mean of 65 days after infection (range 35 to 107 days) revealed encephalitis in the animal with the longest course of the disease. In all the other animals, meningitis alone was found. This was accompanied by a modified early encephalitic reaction, characterized by lympho-plasma-cellular infiltrates exclusively in the adventitial sheaths of those blood vessels passing into the brain from the leptomeninges affected by inflammatory infiltration. The early encephalitic reaction is interpreted as the morphological manifestation of an infestation of the perivascular spaces (Virchow-Robin spaces) with parasites. It indicates that CSF parasitosis in the early phase represents the point of departure for the encephalitis that develops in the late phase of the disease, and that the encephalitis presumably develops as a result of the migration of the trypanosomes out of the subarachnoid space into the perivascular spaces, and from there into the brain.

Entities:  

Mesh:

Year:  1983        PMID: 6407189     DOI: 10.1007/BF00612951

Source DB:  PubMed          Journal:  Virchows Arch A Pathol Anat Histopathol        ISSN: 0174-7398


  4 in total

1.  Pathological aspects of human African trypanosomiasis (HAT) in Uganda. A post-mortem survey of fourteen cases.

Authors:  A A Poltera; R Owor; J N Cox
Journal:  Virchows Arch A Pathol Anat Histol       Date:  1977-04-06

2.  The pathology of African trypanosomiasis.

Authors:  L G Goodwin
Journal:  Trans R Soc Trop Med Hyg       Date:  1970       Impact factor: 2.184

3.  Trypanosoma rhodesiense encephalitis. Clinicopathological study of five cases of encephalitis and one of mel B hemorrhagic encephalopathy.

Authors:  E E Manuelidis; D H Robertson; J M Amberson; M Polak; W Haymaker
Journal:  Acta Neuropathol       Date:  1965-11-18       Impact factor: 17.088

4.  Trypanosoma brucei rhodesiense infection in vervet monkeys. II. Provocation of the encephalitic late phase by treatment of infected monkeys.

Authors:  H Schmidt; P Sayer
Journal:  Tropenmed Parasitol       Date:  1982-12
  4 in total
  15 in total

1.  African trypanosomiasis: haematogenic brain parasitism early in experimental infection through bypassing the blood-brain barrier, with considerations on brain trypanosomiasis in man.

Authors:  H Schmidt; J M Bafort
Journal:  Parasitol Res       Date:  1987       Impact factor: 2.289

2.  Efficacy of the novel diamidine compound 2,5-Bis(4-amidinophenyl)- furan-bis-O-Methlylamidoxime (Pafuramidine, DB289) against Trypanosoma brucei rhodesiense infection in vervet monkeys after oral administration.

Authors:  R E Mdachi; J K Thuita; J M Kagira; J M Ngotho; G A Murilla; J M Ndung'u; R R Tidwell; J E Hall; R Brun
Journal:  Antimicrob Agents Chemother       Date:  2008-12-08       Impact factor: 5.191

3.  Magnetic resonance imaging to assess blood-brain barrier damage in murine trypanosomiasis.

Authors:  Jean Rodgers; Christopher McCabe; George Gettinby; Barbara Bradley; Barrie Condon; Peter G E Kennedy
Journal:  Am J Trop Med Hyg       Date:  2011-02       Impact factor: 2.345

4.  Late stage infection in sleeping sickness.

Authors:  Hartwig Wolburg; Stefan Mogk; Sven Acker; Claudia Frey; Monika Meinert; Caroline Schönfeld; Michael Lazarus; Yoshihiro Urade; Bruno Kilunga Kubata; Michael Duszenko
Journal:  PLoS One       Date:  2012-03-27       Impact factor: 3.240

5.  Intravital imaging of a massive lymphocyte response in the cortical dura of mice after peripheral infection by trypanosomes.

Authors:  Jonathan A Coles; Elmarie Myburgh; Ryan Ritchie; Alana Hamilton; Jean Rodgers; Jeremy C Mottram; Michael P Barrett; James M Brewer
Journal:  PLoS Negl Trop Dis       Date:  2015-04-16

6.  Cyclical appearance of African trypanosomes in the cerebrospinal fluid: new insights in how trypanosomes enter the CNS.

Authors:  Stefan Mogk; Andreas Meiwes; Swetlana Shtopel; Ulrich Schraermeyer; Michael Lazarus; Bruno Kubata; Hartwig Wolburg; Michael Duszenko
Journal:  PLoS One       Date:  2014-03-11       Impact factor: 3.240

7.  Chemotherapy of second stage human African trypanosomiasis: comparison between the parenteral diamidine DB829 and its oral prodrug DB868 in vervet monkeys.

Authors:  John K Thuita; Kristina K Wolf; Grace A Murilla; Arlene S Bridges; David W Boykin; James N Mutuku; Qiang Liu; Susan K Jones; Charles O Gem; Shelley Ching; Richard R Tidwell; Michael Z Wang; Mary F Paine; Reto Brun
Journal:  PLoS Negl Trop Dis       Date:  2015-02-05

8.  Early invasion of brain parenchyma by African trypanosomes.

Authors:  Ute Frevert; Alexandru Movila; Olga V Nikolskaia; Jayne Raper; Zachary B Mackey; Maha Abdulla; James McKerrow; Dennis J Grab
Journal:  PLoS One       Date:  2012-08-31       Impact factor: 3.240

9.  Pharmacology of DB844, an orally active aza analogue of pafuramidine, in a monkey model of second stage human African trypanosomiasis.

Authors:  John K Thuita; Michael Z Wang; John M Kagira; Cathrine L Denton; Mary F Paine; Raymond E Mdachi; Grace A Murilla; Shelley Ching; David W Boykin; Richard R Tidwell; James E Hall; Reto Brun
Journal:  PLoS Negl Trop Dis       Date:  2012-07-24

10.  The blood-brain barrier significantly limits eflornithine entry into Trypanosoma brucei brucei infected mouse brain.

Authors:  Lisa Sanderson; Murat Dogruel; Jean Rodgers; Barbara Bradley; Sarah Ann Thomas
Journal:  J Neurochem       Date:  2008-09-24       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.